Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron's Hunt says next significant milestone will be data from strokes study

Michael Hunt, chief financial officer at ReNeuron (LON:RENE), tells Proactive Investors about the US trial where the first human patient suffering from blindness-causing disease, retinitis pigmentosa, was treated using the company's cell therapy candidate.

He hopes ReNeuron's treatment will "at the very least" arrest the deterioration in eyesight caused by the disease and in the best case restore sight.

Hunt hopes to get first data for retinitis pigmentosa Phase I/II US trial before end 2016. Subject to the outcome of this study, he expects ReNeuron to be able to file an application in the second half of 2017 to commence a pivotal Phase II/III clinical trial with its cell therapy candidate.

He says the next significant milestone for the company if all goes well will be the data from its strokes study in a Phase II clinical trial in the UK.

 
Meet Allergy Therapeutics plc, Cello Group plc, Sphere Medical Holding PLC and ValiRx Plc at our event, London, 06 October 2016. Register here »
View full RENE profile

ReNeuron Group Plc Timeline

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.